Dr. Abel Jarell reviews findings from a poster on the 31-GEP test’s role in identifying CNS metastasis risk in patients with stage I–II cutaneous melanoma.
Topics Covered:
Explore Related Resources:
Evaluating Melanoma Survival Stratification and Gene Testing
Brent Moody, MD: Assessing the Prognostic Significance of the 31-gene Expression Profile Test
Dr. Moody discusses a poster presented at the 2025 Fall Clinical Dermatology Conference that evaluated the 31-GEP test across all melanoma subtypes. Reference: Marks E...
PLAY
Hadas Skupsky, MD, FAAD: Pigmented Lesion Management for the Dermatologist
Dr. Skupsky details how dermatologists can use ancillary testing to guide their decision making on atypical pigmented lesions.
PLAY
Dr. Rizzo discusses research that he and his co-authors presented at the 2025 AAD Annual Meeting, which validated the performance of the 31-gene expression profile...
PLAY